News · 26 weeks69+300%
2026-03-012026-08-23
Mix2090d
- Insider11(55%)
- Other4(20%)
- SEC Filings3(15%)
- Earnings2(10%)
Latest news
25 items- INSIDERDirector Roeder Douglas A bought $125,300 worth of shares (13,953 units at $8.98), increasing direct ownership by 9% to 171,191 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- SECSEC Form 10-Q filed by Senseonics Holdings Inc.10-Q - Senseonics Holdings, Inc. (0001616543) (Filer)
- SECSenseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRSenseonics Holdings, Inc. Reports Second Quarter 2026 Financial ResultsGenerated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-yearRaising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58% GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 20
- PRSenseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern TimeGERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Even
- INSIDERDirector Fiorentino Edward was granted 2,635 shares, increasing direct ownership by 3% to 85,974 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Prince Douglas S was granted 1,515 shares, increasing direct ownership by 2% to 69,331 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Roeder Douglas A was granted 2,751 shares, increasing direct ownership by 2% to 157,238 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Steven Edelman was granted 2,402 shares, increasing direct ownership by 3% to 91,083 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERChief Medical Officer Kaufman Francine covered exercise/tax liability with 4,010 shares, decreasing direct ownership by 2% to 177,057 units (SEC Form 4) to cover taxes4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERPresident and CEO Goodnow Timothy T covered exercise/tax liability with 32,598 shares, decreasing direct ownership by 3% to 1,143,748 units (SEC Form 4) (withholding obligation)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERGC & Corp. Development Advisor Horton Kenneth L covered exercise/tax liability with 9,545 shares, decreasing direct ownership by 3% to 285,512 units (SEC Form 4) to satisfy tax liability4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERChief Commercial Officer Hansen Brian B covered exercise/tax liability with 5,420 shares, decreasing direct ownership by 4% to 126,937 units (SEC Form 4) to satisfy tax liability4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERChief Operating Officer Jain Mukul covered exercise/tax liability with 16,194 shares, decreasing direct ownership by 3% to 500,863 units (SEC Form 4) to cover withholding tax4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERChief Financial Officer Sullivan Frederick T. covered exercise/tax liability with 5,397 shares, decreasing direct ownership by 2% to 226,477 units (SEC Form 4) to satisfy withholding obligation4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- PRSenseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365The new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is expected to launch in the second half of 2026 GERMANTOWN, Md. and COLUMBIA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Senseonics, a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, and Welldoc®, a leader in AI-powered health solutions, today announce a strategic partnership to develop a new custom mobile application for Eversense® 365. The next-generation app will maintain all existing features that patients currently benefit from, alongside new features to enhance user exp
- SECSenseonics Holdings Inc. filed SEC Form 8-K: Other Events8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRReal-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop SystemsEversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance New data expands on findings shared at ATTD and reinforces Eversense 365's strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals
- SECSEC Form SD filed by Senseonics Holdings Inc.SD - Senseonics Holdings, Inc. (0001616543) (Filer)
- PRSenseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics
- INSIDERChief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERGC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERChief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Fiorentino Edward was granted 9,852 shares, increasing direct ownership by 13% to 83,339 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
- INSIDERDirector Defalco Stephen P was granted 9,852 shares, increasing direct ownership by 10% to 111,019 units (SEC Form 4)4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
SENS FAQ
6 questionsWhat does Senseonics Holdings Inc. do?
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through...Where does SENS stock trade?
Senseonics Holdings Inc. (SENS) is listed on AMEX.What sector and industry is SENS in?
Senseonics Holdings Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about SENS?
Senseonics Holdings Inc. has had 7 recent analyst actions on file. The most recent action was from Stifel: Hold with a $900.00 price target on 2025-10-21.What companies are similar to SENS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SENS side-by-side with any of them on Quantisnow.How can I track SENS on Quantisnow?
Quantisnow aggregates Senseonics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SENS to receive live email and push alerts on every new disclosure.